<

Margaret Frame

Director: CRUK Edinburgh Cancer Research Centre; Director: MRC Institute of Genetics and Molecular Medicine (MRC-IGMM) , United Kingdom



Margaret Frame is a biomedical research scientist with interests in novel cancer mechanisms, as evidenced by deep biology, imaging and new approaches to drug discovery and cancer therapeutics – work that has been funded by five successive CRUK (or predecessor charity) Programme grants and more recently also by an ERC Advanced Investigator Grant.
From 2002-2007, Margaret was Deputy Director of the core funded CRUK Beatson Institute for Cancer Research in Glasgow, after which she moved to the University of Edinburgh (UoE). Currently she is Professor of Cancer Research, Director of the CRUK Edinburgh Cancer Centre and Director of the MRC-IGMM (Institute of Genetics and Molecular Medicine), having recently stepped down as Dean of Research in the College of Medicine and Veterinary Medicine (UoE). Margaret is very active in supporting the scientific careers of early- and mid-stage researchers (the MRC-IGMM has 25 early-career Chancellor’s Fellows, 20 of whom have won personal fellowships or substantial other grant funding). She supports early career researchers, both clinical and non-clinical, an interest that stems from her time as Chairman of the CRUK New Investigator Panel and from her own experiences when building a research career during the ‘young family’ years (3 adult sons). She is currently co-Chair of the Academy of Medical Sciences Careers Committee and member of Lister Institute Scientific Advisory Committee, a Wellcome Trust Expert Review Group and an ERC Funding Panel, as well as chairman, or member, of several international scientific advisory boards.
Margaret was awarded the Tenovus Medal in 1999, and was elected a Fellow of the Royal Society of Edinburgh in 2002, an EMBO Member in 2007 and a Fellow of the Academy of Medical Sciences in 2009. She was awarded the Chancellor’s prize for Research - presented by HRH The Princess Royal (the Chancellor of the University of Edinburgh). She recently served as President of the British Association for Cancer Research and Chaired the 2018 National (UK) Cancer Research Institute meeting. She was awarded an OBE in the Queen’s Honours List in 2018 for services to cancer research.

Patrick Tan 

Duke-NUS Medical School, Singapore



Professor Patrick Tan is a professor at the Duke-NUS Medical School and Deputy Executive Director of the Biomedical Research Council (Agency for Science, Technology and Research). He directs PRISM, the SingHealth Duke-NUS Institute of Precision Medicine, and was Program Director of POLARIS which established the first CAP-certified facilities for next-generation sequencing and the first clinically implemented NGS panel in South East Asia, which to date has been been applied to >1000 cancer patients.
He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other awards include the President’s Scholarship, Loke Cheng Kim scholarship, Young Scientist Award (A-STAR), Singapore Youth Award (twice), SingHealth Investigator Excellence Award, Chen New Investigator Award (Human Genome Organization), President’s Science Award, and the Japanese Cancer Association International Award. In 2018, he received the American Association for Cancer Research (AACR) Team Science Award as Team Leader, representing the first time a team from Asia has received the award. He is an elected member of the American Society for Clinical Investigation (ASCI), the Bioethics Advisory Committee (BAC), a Board Member of the International Gastric Cancer Association, and co-chair of the Singapore National Precision Medicine Program Steering Committee.

Nada Jabado

McGill University Montreal, QC, CANADA


Dr Nada Jabado is a Professor of Pediatrics at McGill University and pediatric neuro-oncologist at the Montreal Children’s Hospital. She completed her residency in pediatrics with a specialization in hemato-oncology. She also obtained a PhD in Immunology in Paris, France, followed by a postdoctoral fellowship in biochemistry at McGill. She began her career as an independent investigator at McGill in 2003, pioneering a research program in pediatric brain tumors which is now unparalleled. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1).
Dr. Jabado's ground-breaking work has created a paradigm shift in cancer with the identification of histone mutations in human disease which has revolutionized this field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetic-driven cancers. She has over 160 peer-reviewed publications to her credit, with an impressive number of senior-author, high-impact publications in such prominent journals as Nature Genetics, Nature, Science and Cancer Cell, to name a few. She has over 16,000 citations and an h-index of 67 and many of her publications are considered landmark papers. Nada is an international leader in the field of neuro-oncology/cancer, honored by invitations as s keynote speaker at top ranked symposia and universities. Dr. Jabado has received numerous national and international honors while garnering prestigious salary support awards throughout her career. She is one of the best-funded investigators in Canada, with grants from CIHR, Genome Canada, NIH as well as philanthropic organizations. She has been inducted as a Fellow to the Royal Society of Canada, a member of the CIHR Governing Council, a member of the Canadian Academy of Health Sciences and was recently awarded the Israel Cancer Research Fund Award for Women of Action.

Kristin Brown

Peter MacCallum Cancer Centre



Melbourne, Australia

Christine Chaffer

Garvan Institute



Sydney, Australia



Roger Daly

Monash Biomedicine Discovery Institute, Monash University



Melbourne, Australia

Melissa Davis

Walter and Eliza Hall Institute



Melbourne, Australia

Ruth Ganss

Harry Perkins Institute, UWA



Perth, Australia

Jeff Holst

University of Sydney



Sydney, Australia

Nick Huntington

Monash Biomedicine Discovery Institute, Monash University



Melbourne, Australia

Peter Janes

Olivia Newton John Cancer Research Institute



Melbourne, Australia

Laura Mackay

Doherty Institute



Melbourne, Australia

Christina Mitchell

Monash Biomedicine Discovery Institute, Monash University



Melbourne, Australia

Jane Oliaro

Peter MacCallum Cancer Centre



Melbourne, Australia

Marina Pajic

Garvan Institute



Sydney, Australia



Stuart Pitson

Centre for Cancer Biology, University of Adelaide



Adelaide, Australia



Sefi Rosenbluh

Hudson Institute of Medical Research & Monash Biomedicine Discovery Institute, Monash University



Melbourne, Australia

Michael Samuel

Centre for Cancer Biology



Adelaide, Australia

Andrew Scott

Olivia Newton John Cancer Research Institute



Melbourne, Australia

Paul Timpson

Garvan Institute



Sydney, Australia

David Waugh

Queensland University of Technology



Brisbane, Australia

Sarah Best

Walter and Eliza Hall Institute, Melbourne



Dr Sarah Best's research focuses on identifying targetable driver mutations in epithelial tumours, and modelling these mutations in GEMMs. Dr Best completed her PhD in breast cancer research at the WEHI, before undertaking a Postdoctoral Fellowship at the Brigham and Women’s Hospital/Harvard Medical School in non-melanoma skin cancer. In 2016, Dr Best returned to the WEHI in the internationally-renowned lung cancer research laboratory under the mentorship of Dr Kate Sutherland. Dr Sutherland’s research program is dedicated to understanding the drivers of inter-tumoural heterogeneity in lung cancer, with the aim of designing precision medicine approaches for patients.

TBA

TBA



...

TBA (TBA)

...

TBA (TBA)

...

TBA (TBA)

...

© 2019 Monash University